Kentucky Retirement Systems trimmed its stake in McKesson Co. (NYSE:MCK – Free Report) by 1.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,795 shares of the company’s stock after selling 185 shares during the period. Kentucky Retirement Systems’ holdings in McKesson were worth $5,721,000 at the end of the most recent quarter.
A number of other hedge funds have also recently modified their holdings of the stock. Hsbc Holdings PLC grew its position in shares of McKesson by 2.4% in the 2nd quarter. Hsbc Holdings PLC now owns 275,077 shares of the company’s stock valued at $161,123,000 after buying an additional 6,377 shares during the last quarter. Waterloo Capital L.P. purchased a new position in shares of McKesson in the 2nd quarter valued at $246,000. Zega Financial LLC purchased a new position in shares of McKesson in the 2nd quarter valued at $1,829,000. Vanguard Personalized Indexing Management LLC grew its position in shares of McKesson by 12.2% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 15,222 shares of the company’s stock valued at $8,747,000 after buying an additional 1,654 shares during the last quarter. Finally, Tredje AP fonden grew its position in McKesson by 5.8% during the 2nd quarter. Tredje AP fonden now owns 104,969 shares of the company’s stock worth $61,306,000 after purchasing an additional 5,764 shares during the last quarter. 85.07% of the stock is owned by hedge funds and other institutional investors.
Insider Transactions at McKesson
In other news, CEO Brian S. Tyler sold 3,753 shares of McKesson stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $626.03, for a total transaction of $2,349,490.59. Following the completion of the sale, the chief executive officer now directly owns 82,339 shares in the company, valued at $51,546,684.17. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold a total of 11,259 shares of company stock worth $6,635,492 over the last ninety days. 0.11% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades
Check Out Our Latest Research Report on McKesson
McKesson Trading Down 0.7 %
Shares of MCK opened at $507.95 on Friday. The stock has a market cap of $66.00 billion, a P/E ratio of 22.70, a PEG ratio of 1.18 and a beta of 0.44. McKesson Co. has a 12-month low of $431.35 and a 12-month high of $637.51. The company has a 50-day moving average of $561.63 and a two-hundred day moving average of $557.00.
McKesson (NYSE:MCK – Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $7.88 EPS for the quarter, topping analysts’ consensus estimates of $7.21 by $0.67. The business had revenue of $79.28 billion during the quarter, compared to the consensus estimate of $82.53 billion. McKesson had a net margin of 0.94% and a negative return on equity of 242.57%. The company’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $7.27 earnings per share. As a group, analysts forecast that McKesson Co. will post 32.11 EPS for the current fiscal year.
McKesson Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 1st. Stockholders of record on Monday, September 2nd will be issued a dividend of $0.71 per share. The ex-dividend date is Friday, August 30th. This is an increase from McKesson’s previous quarterly dividend of $0.62. This represents a $2.84 dividend on an annualized basis and a dividend yield of 0.56%. McKesson’s payout ratio is 12.69%.
McKesson Profile
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
See Also
- Five stocks we like better than McKesson
- What is the Dogs of the Dow Strategy? Overview and Examples
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- Stock Analyst Ratings and Canadian Analyst Ratings
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.